Related references
Note: Only part of the references are listed.Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS)
K. Pietzner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Have we overestimated the benefit of human(ized) antibodies?
Daniel R. Getts et al.
MABS (2010)
Functional and clinical consequences of Fc receptor polymorphic and copy number variants
S. Bournazos et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2009)
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Jonathan Berek et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis
Michael A. Stroehlein et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Monoclonal antibodies for cancer immunotherapy
Louis M. Weiner et al.
LANCET (2009)
Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody
Shoshana Morecki et al.
EXPERIMENTAL HEMATOLOGY (2008)
Characterisation of the new EpCAM-specific antibody HO-3:: implications for trifunctional antibody immunotherapy of cancer
P. Ruf et al.
BRITISH JOURNAL OF CANCER (2007)
Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies
Ignacio Azinovic et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Intraperitioneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma
A Marmé et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
P Ruf et al.
BLOOD (2001)
Share Paper
